Pain Therapeutics (NASDAQ:PTIE)’s REMOXY Receives Rejection Notice: Shares Plummeting

Shares of Pain Therapeutics (NASDAQ:PTIE) are under heavy selling pressure today after the FDA rejected their NDA drug, the firm noted in a press release this morning.

CUPERTINO, Calif., Sept. 26, 2016 /PRNewswire/ — DURECT Corporation (DRRX) today announced that its licensee, Pain Therapeutics (PTIE) has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Pain Therapeutics’ New Drug Application (NDA) for REMOXY® ER (oxycodone) extended-release capsules CII.  Based on its review, the FDA has determined that the NDA cannot be approved in its present form and specifies additional actions and data that are needed for drug approval.

In a press release issued this morning by Pain Therapeutics, Pain Therapeutics states that “The CRL focuses on the abuse-deterrent properties of REMOXY ER and proposed drug labeling.  The CRL makes no mention of clinical safety, drug efficacy, manufacturing, stability, bioequivalence or any other issues from a prior Complete Response Letter.” 

The announcement continues that “Pain Therapeutics is evaluating the CRL and plan further discussions with the FDA.  The CRL specifies additional actions that are needed in order to obtain approval of REMOXY ER with label claims against three routes of abuse (i.e., injection, inhalation and snorting).  These actions may take approximately a year to conduct and may cost approximately $5MM, pending discussions with the FDA and outside clinical/regulatory consultants.”

In addition, the Pain Therapeutics provides the following details of the Complete Response Letter (CRL):

“The CRL focuses on the actions and studies that are needed in order to obtain approval of REMOXY ER with label claims on three routes of abuse (i.e., injection, inhalation and snorting). In conducting the following studies, we will generally compare REMOXY ER vs. one or more commercially available oxycodone ER drug product:  

  • To support a potential drug label claim against abuse by injection: Repeat an injectability/syringeability study using thin films of drug, smaller volumes of solvents, additional mixed solvents and alternative extraction methods and syringe filter.
  • To support a potential drug label claim against abuse by inhalation: Repeat a volatilization study using the same thickness for each drug to increase surface area.
  • To support a potential drug label claim against abuse by snorting: Conduct an intranasal abuse potential study in human volunteers (i.e., not the animal data we had submitted) with drug applied directly inside the human nasal cavity.

In addition, we had proposed in the REMOXY NDA a label claim against abuse by chewing.  Our proposal was based on clinical results of an oral human abuse potential study that met all four co-primary endpoints with statistical significance and that also met several, but not all, secondary endpoints.  The CRL asks us to submit a revised proposed label to indicate results of this study do not support a label claim against abuse by chewing.”

In December 2002, DURECT licensed to Pain Therapeutics the exclusive right to develop and commercialize on a worldwide basis REMOXY ER  and other specified opioid analgesics utilizing DURECT’s ORADUR extended-release, abuse-deterrent technology. Under the terms of that license, Pain Therapeutics funds the development program including reimbursing DURECT for formulation and other work performed for Pain Therapeutics.  DURECT may also receive additional payments if certain development and regulatory milestones are achieved.  DURECT is eligible to also receive royalties of between 6.0% to 11.5% of net sales if REMOXY ER is commercialized, and may receive additional income from the sale of key excipients supplied by DURECT for use in the manufacture of REMOXY ER.

Original Source

Sign up to Our Newsletter and Receive Breaking Alerts on Stocks that are Ready to Explode!

Sign up to get our Free Penny Stock Picks Before the Street!

Pain Therapeutics (NASDAQ:PTIE) is trading -53.883% at the time of writing and in the range of 0.960 – 1.370 for the current session.

Looking out to a consensus level, sell-side research analysts have a price target of 6.000 on Pain Therapeutics. This is the average taken from the individual targets provided by covering analysts polled by Thomson Reuters First Call. Analysts are anticipating that the company will report earnings of -0.090 per share for next quarter. For the current year, research firms are anticipating earnings of -0.460 per share.

Technical Look

On a technical level the stock has a 50 Day Moving Average of 2.499. Based on a recent trade, this puts the equity at -49.623% away from that average. In comparing the stock’s current level to its extended history, the stock is trading -58.033% away from its 52 week high of 3.000 and +31.146% away from the stock’s low point over the past 52 weeks, which was 0.960.

Today the stock opened the current trading session at 0.980 and at the time of writing the last Bid was at 1.259. In the current session the stock reached as high as 1.370 and dipped down to 0.960. Pain Therapeutics, a 58.09M listed company, has a current market cap of 230219.

Sign up to get our Free Penny Stock Picks Before the Street!

BRKK is One of the Most Under the Radar Penny Stocks We've Ever Seen. View the free report here.


Related posts

Leave a Comment